These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36672491)

  • 21. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK.
    Akbar A; Orchard T; Powell N; Selinger C; Tibbatts C
    Frontline Gastroenterol; 2022; 13(6):490-496. PubMed ID: 36250175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
    Vedamurthy A; Gangasani N; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study.
    Wlazło M; Meglicka M; Wiernicka A; Osiecki M; Kierkuś J
    Children (Basel); 2022 Dec; 10(1):. PubMed ID: 36670562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated Crohn's Colitis: Is Localization Crucial? Characteristics of Pediatric Patients From the CEDATA-GPGE Registry.
    Elonen L; Wölfle L; de Laffolie J; Posovszky C;
    Front Pediatr; 2022; 10():875938. PubMed ID: 35712614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
    Gold SL; Steinlauf AF
    Gastroenterol Hepatol (N Y); 2021 Sep; 17(9):406-414. PubMed ID: 34602905
    [No Abstract]   [Full Text] [Related]  

  • 28. Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.
    Wilson M; Lucas A; Cameron A; Luo M
    Am Health Drug Benefits; 2018 Jul; 11(5):253-262. PubMed ID: 30464793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.
    Luzentales-Simpson M; Pang YCF; Zhang A; Sousa JA; Sly LM
    Front Cell Dev Biol; 2021; 9():612830. PubMed ID: 33614645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.
    Wetwittayakhlang P; Lakatos PL
    J Can Assoc Gastroenterol; 2024 Feb; 7(1):22-29. PubMed ID: 38314172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epidemiology of inflammatory bowel disease.
    Burisch J; Munkholm P
    Scand J Gastroenterol; 2015 Aug; 50(8):942-51. PubMed ID: 25687629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
    Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia.
    AlRuthia Y; Alharbi O; Aljebreen AM; Azzam NA; Almadi MA; Bahari OH; Almalki KA; Atham AT; Alanazi AS; Saeed M; HajkhderMullaissa B; Alsenaidy M; Balkhi B
    Cost Eff Resour Alloc; 2019; 17():25. PubMed ID: 31827409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.